Literature DB >> 33486526

An Open-Label, Randomized, Controlled, Crossover Study to Assess Nicotine Pharmacokinetics and Subjective Effects of the JUUL System with Three Nicotine Concentrations Relative to Combustible Cigarettes in Adult Smokers.

Nicholas I Goldenson1, Ian M Fearon2, August R Buchhalter3, Jack E Henningfield3.   

Abstract

INTRODUCTION: This randomized, open-label, crossover clinical study evaluated nicotine pharmacokinetics (PK) and subjective effects of the JUUL System (JS; Juul Labs, Inc.) with three nicotine concentrations compared to the usual brand (UB) cigarettes in 24 adult smokers.
METHODS: At five study visits, subjects used either the JS in 59 mg/mL, JS 18 mg/mL (two visits), and JS 9 mg/mL (all tobacco-flavored) or smoked their UB cigarette first during a controlled puffing sequence (CPS) and then ad libitum (5 min) use sessions. Blood samples were taken at specified timepoints for 60 min in each session. The modified Product Evaluation Scale assessed subjective effects 30-min post-use in the CPS session.
RESULTS: Maximum plasma nicotine concentration (Cmax-BL), total nicotine exposure (AUC0-60-BL), and rate of plasma nicotine rise were significantly lower for all JS products compared to subjects' UB cigarette in CPS and ad libitum use sessions. In both use sessions these PK parameters were significantly higher for JS 59 mg/mL compared to 18 and 9 mg/mL. Subjective measures of cigarette craving relief and "Enough Nicotine" for JS 59 mg/mL did not differ significantly from UB cigarettes, but JS 18 and 9 mg/mL were rated significantly lower than JS 59 mg/mL and UB cigarettes.
CONCLUSIONS: Nicotine exposure and subjective relief were directly related to JS nicotine concentration: higher nicotine concentrations gave rise to significantly greater plasma nicotine levels and relief from craving. Heavier and more dependent smokers may require the greater nicotine delivery of JS 59 mg/mL to successfully transition away from cigarettes. IMPLICATIONS: It has been suggested that electronic nicotine delivery systems (ENDS) and other alternative nicotine delivery products that more closely mimic the nicotine pharmacokinetics (PK) of cigarettes may facilitate smokers transitioning away from cigarettes. We examined nicotine PK and subjective effects of JUUL System (JS) ENDS with three nicotine concentrations (59, 18 and 9 mg/mL) compared to combustible cigarettes. Nicotine delivery from JS ENDS was nicotine concentration dependent, with higher nicotine concentrations giving rise to higher nicotine exposure. These findings suggest that heavier and more dependent smokers may require ENDS with nicotine concentrations greater than 20 mg/mL to successfully transition away from cigarettes.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco.

Entities:  

Year:  2021        PMID: 33486526     DOI: 10.1093/ntr/ntab001

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  6 in total

1.  A randomised, crossover, clinical study to assess nicotine pharmacokinetics and subjective effects of the BIDI® stick ENDS compared with combustible cigarettes and a comparator ENDS in adult smokers.

Authors:  Ian M Fearon; Karin Gilligan; Ryan G N Seltzer; Willie McKinney
Journal:  Harm Reduct J       Date:  2022-06-02

2.  Nicotine delivery and relief of craving after consumption of European JUUL e-cigarettes prior and after pod modification.

Authors:  Nadja Mallock; Andrea Rabenstein; Solveig Gernun; Peter Laux; Christoph Hutzler; Susanne Karch; Gabriele Koller; Frank Henkler-Stephani; Maria Kristina Parr; Oliver Pogarell; Andreas Luch; Tobias Rüther
Journal:  Sci Rep       Date:  2021-06-08       Impact factor: 4.379

3.  Drug and alcohol dependence acute effects of pod-style e-cigarettes in vaping-naïve smokers.

Authors:  Natalia Peraza; Mariel S Bello; Sara J Schiff; Junhan Cho; Yi Zhang; Carly Callahan; Alayna Tackett; Adam M Leventhal
Journal:  Drug Alcohol Depend       Date:  2021-09-21       Impact factor: 4.492

4.  Trends in e-cigarette brands, devices and the nicotine profile of products used by youth in England, Canada and the USA: 2017-2019.

Authors:  David Hammond; Jessica L Reid; Robin Burkhalter; Richard J O'Connor; Maciej L Goniewicz; Olivia A Wackowski; James F Thrasher; Sara C Hitchman
Journal:  Tob Control       Date:  2021-06-07       Impact factor: 6.953

Review 5.  Nicotine delivery and cigarette equivalents from vaping a JUULpod.

Authors:  Judith J Prochaska; Erin A Vogel; Neal Benowitz
Journal:  Tob Control       Date:  2021-03-24       Impact factor: 6.953

6.  Consumption of JUUL vs. Other E-Cigarette Brands among U.S. E-Cigarette Users: Evidence from Wave 5 of the PATH Study.

Authors:  Yu Wang; Zongshuan Duan; Scott R Weaver; Lucy Popova; Claire A Spears; David L Ashley; Terry F Pechacek; Michael P Eriksen; Jidong Huang
Journal:  Int J Environ Res Public Health       Date:  2022-08-31       Impact factor: 4.614

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.